{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095460","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-08-13T11:25:27+00:00","discovered_at":"2026-08-13T11:30:00.475732+00:00","generated_at":"2026-08-13T11:30:16.502389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cellectar Q2 net loss $6.9M; cash $34M; Phase 3 iopofosine trial site activation started","bullets":["Net loss $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025; R&D up to $4.6M from $2.4M.","Cash $34.0M at June 30, 2026 vs $13.2M at Dec 31, 2025; funded into Q2 2027.","Initiated site activation for confirmatory Phase 3 iopofosine I 131 in WM; NDA planned mid-2027 under accelerated approval.","Dosed first patients in Phase 1b CLR 125 for triple-negative breast cancer.","May 2026 financing: ~$35M upfront, up to $105M milestone-based securities to fund Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095460","json":"https://secwatch.observer/filing/0001104659-26-095460.json","markdown":"https://secwatch.observer/filing/0001104659-26-095460.md","text":"https://secwatch.observer/filing/0001104659-26-095460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/0001104659-26-095460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:30:16.502389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}